Adagio Medical to Participate in the 38th Annual Roth Conference

Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a prominent medical device company specializing in catheter ablation technologies for cardiac arrhythmias, has announced its participation in the 38th Annual Roth Conference, scheduled for March 23-24, 2026, in Laguna Niguel, CA. At this influential event, Adagio's management team will host one-on-one meetings with investors to discuss the company's innovations and growth strategies. Interested parties can either contact their Roth representative or email ir@adagiomedical.com to schedule a meeting.

Adagio is particularly recognized for its proprietary Ultra-Low Temperature Cardiac (ULTA) ablation technology, which is designed to create substantial, long-lasting lesions in both diseased and healthy cardiac tissue. The company is currently focusing on the treatment of ventricular arrhythmias through its specialized vCLAS™ Cryoablation System, which holds a CE Mark and is also under evaluation in the pivotal FULCRUM-VT trial in the U.S.

The FULCRUM-VT trial, which stands for Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia, is a significant, prospective multi-center study that has fully enrolled 209 patients with structural heart issues. This trial aims to assess the efficacy of the vCLAS™ system for patients suffering from drug-refractory ventricular tachycardia. The results garnered from this study will potentially serve as a basis for Adagio's application for FDA premarket approval, aiming to establish one of the broadest indications for endocardial ablation of scar-mediated ventricular tachycardia.

Currently, while the vCLAS™ system is available for commercial use in Europe and select markets, it remains investigational in the U.S., highlighting the critical importance of the upcoming clinical trial results.

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is poised for a significant opportunity as it prepares to participate in the 38th Annual Roth Conference on March 23-24, 2026. The event will allow management to engage directly with potential investors and stakeholders, providing an excellent platform to discuss the company’s innovative catheter ablation technologies targeting cardiac arrhythmias.

Investors should be particularly keen on the developments surrounding Adagio's vCLAS™ Cryoablation System, which utilizes proprietary Ultra-Low Temperature (ULTA) technology. This system is designed to treat ventricular arrhythmias, a critical area in cardiology that presents substantial market potential. With the FULCRUM-VT clinical trial fully enrolled and underway, the data produced from this study is crucial for seeking FDA premarket approval (PMA), which could expand Adagio's market reach significantly in the U.S.

The vCLAS™ system is already commercially available in Europe, providing a revenue stream as the company awaits FDA validation. Its innovative edge in creating large, durable lesions through both diseased and healthy tissue underscores its potential efficacy and could position Adagio favorably against established competitors in the cardiac device market.

As investors consider Adagio Medical, it is essential to monitor the upcoming announcements from the Roth Conference and any developments related to the FULCRUM-VT trial outcomes. Positive results could spur a surge in investor interest and stock price appreciation, given the regulatory implications and potential market expansion.

Overall, positioning within Adagio Medical offers a speculative yet promising opportunity, particularly as it navigates the critical milestones of FDA approval and market introduction. It would be prudent for investors to keep a close watch on Adagio's strategic moves and trial results as they could significantly influence the company's future trajectory.